NCT01622569.

Trial name or title	'Study evaluating the efficacy and safety of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day (bid) using a novel bi directional device in subjects with bilateral nasal polyposis followed by an 8‐week open‐label extension phase to assess safety'
Methods	Double‐blind, parallel assignment, randomised controlled trial
Participants	Adults with bilateral nasal polyposis
Interventions	‐ Fluticasone propionate 100 μg twice a day ‐ Fluticasone propionate 200 μg twice a day ‐ Fluticasone propionate 400 μg twice a day ‐ Matching placebo For 16 weeks
Outcomes	‐ Reduction of nasal congestion/obstruction symptoms ‐ Reduction in total polyp grade (sum of scores from both nasal cavities) No secondary outcomes were listed in the trial registry entry
Starting date	2013
Contact information	Optinose US Inc. No further details provided.
Notes	Study has been listed as completed on the registry website (October 2015). No results are currently available.